Jounce Therapeutics (JNCE) Receives Downgrade From Wells Fargo. Will Other Analysts Follow Suit?

May 17, 2018 - By Tina Thibodeau

Jounce Therapeutics (JNCE) Receives a Downgrade

Wells Fargo has given Jounce Therapeutics (JNCE) shares a new Market Perform rating in analysts note sent to clients and investors on Thursday morning. This was a downgrade from the last Outperform rating.

Jounce Therapeutics, Inc. (NASDAQ:JNCE) Ratings Coverage

Among 2 analysts covering Jounce Therapeutics Inc (JNCE), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Jounce Therapeutics Inc has $35.0 highest and $33 lowest target. $34’s average target is 196.94% above currents $11.45 stock price. Jounce Therapeutics Inc had 2 analyst reports since March 8, 2018 according to SRatingsIntel. Robert W. Baird maintained it with “Buy” rating and $35.0 target in Thursday, March 8 report.

The stock decreased 35.20% or $6.22 during the last trading session, reaching $11.45. About 6.87M shares traded or 1705.63% up from the average. Jounce Therapeutics, Inc. (JNCE) has declined 9.84% since May 18, 2017 and is downtrending. It has underperformed by 21.39% the S&P500.

Analysts await Jounce Therapeutics, Inc. (NASDAQ:JNCE) to report earnings on August, 8. They expect $-0.38 EPS, down 245.45 % or $0.27 from last year’s $-0.11 per share. After $-0.40 actual EPS reported by Jounce Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -5.00 % EPS growth.

Jounce Therapeutics, Inc., a clinical stage immunotherapy company, focuses on developing therapies that enable the immune system to attack tumors. The company has market cap of $371.94 million. The Company’s lead product candidate, JTX-2011, is a clinical stage monoclonal antibody that binds to and activates ICOS, a protein on the surface of certain T cells commonly found in various solid tumors. It currently has negative earnings. The firm is also developing JTX-4014, an anti-PD-1 antibody.

More notable recent Jounce Therapeutics, Inc. (NASDAQ:JNCE) news were published by: Seekingalpha.com which released: “Jounce Therapeutics’ (JNCE) CEO Rich Murray on Q1 2018 Results – Earnings Call Transcript” on May 09, 2018, also Nasdaq.com with their article: “Mid-Afternoon Market Update: Dow Turns Lower; JC Penney Shares Plunge” published on May 17, 2018, 247Wallst.com published: “Why Jounce Shares Are Crumbling Ahead of ASCO” on May 17, 2018. More interesting news about Jounce Therapeutics, Inc. (NASDAQ:JNCE) were released by: Streetinsider.com and their article: “Pre-Open Movers 05/17: (WWE) (LOXO) (NTES) Higher; (JNCE) (JCP) (ACXM) Lower (more…)” published on May 17, 2018 as well as Streetinsider.com‘s news article titled: “Jounce Therapeutics (JNCE) option implied volatility elevated, to present data from ICONIC trial at ASCO” with publication date: May 17, 2018.

Jounce Therapeutics, Inc. (NASDAQ:JNCE) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: